# AIPher

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aipher

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Total disclosed funding: $15M
- Latest round: Angel (Sep 3, 2026)
- Investors on record: 2

## About

Based in Beijing, China, and founded in 2026, AIPher (Beijing) Pharmaceutical Technology Co., Ltd., trading as AlPher, is an AI-native drug developer focusing on AI-driven innovative drug development. It collaborates with pharmaceutical companies, biotech companies, and research institutions through a co-development model, covering the entire process from target discovery, molecular design, and experimental validation to candidate drug optimization. In September 2026, AIPher raised CNY 100 million in Angel funding led by Xiang He Capital, with participation from Xinglian Capital and other investors.

The company provides AI-enabled drug discovery and co-development services for pharmaceutical and biotechnology partners.

The company generates revenue through co-development partnerships, milestone payments, licensing agreements, and downstream revenue-sharing arrangements related to drug development programs.

The Angel funding raised in September 2026 will primarily be used for the continued development of drug-based models represented by DrugCLIP and the AI ??drug development intelligent engine PharmAgents.

## Funding rounds

- Angel, Sep 3, 2026, $15M — Xiang He Capital, Xinglian Capital

## Investors

- Xiang He Capital (https://capitalatlas.ai/funds/xiang-he-capital) — Angel
- Xinglian Capital (https://capitalatlas.ai/funds/xinglian-capital) — Angel